# Phase 2 Study - Erdosteine in Patients With CB/COPD

> **NCT00338507** · PHASE2 · COMPLETED · sponsor: **Adams Respiratory Therapeutics** · enrollment: 400 (—)

## Conditions studied

- Chronic Bronchitis
- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Erdosteine

## Key facts

- **NCT ID:** NCT00338507
- **Lead sponsor:** Adams Respiratory Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 400 (—)
- **Last updated:** 2007-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00338507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00338507, "Phase 2 Study - Erdosteine in Patients With CB/COPD". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00338507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*